Therapeutic efficacy of transarterial chemo-embolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma

Table 2 Univariate and multivariate analysis of predictors of survival

Variable	Hazard ratio	95%CI	P value
Univariate analysis of predictors of survival
Age ( ≤ 65 vs > 65 yr)	1.085	0.772-1.525	0.638
Gender (M vs F)	0.861	0.607-1.222	0.403
Previous treatment (no vs yes)	1.258	0.911-1.738	0.164
HCV antibody (negative vs positive)	0.951	0.673-1.344	0.776
Stage (I, II, III vs IV)	2.705	1.919-3.814	< 0.001
Child Pugh classification (A vs B or C)	1.584	1.149-2.184	0.005
JIS score (0-2 vs 3-5)	2.285	1.638-3.189	< 0.001
Total bilirubin ( ≤ 1.5 mg/dL vs > 1.5 mg/dL)	1.578	1.044-2.385	0.031
Albumin (> 3.5 mg/dL vs ≤ 3.5 mg/dL)	1.527	1.100-2.119	0.012
Number of tumors (< 10 vs≥ 10)	1.920	1.378-2.675	< 0.001
Maximum tumor size ( ≤ 50 mm vs > 50 mm)	2.052	1.404-2.998	< 0.001
PVTT grade (Vp0, 1, 2 vs Vp3)	4.142	2.754-6.230	< 0.001
Tumor distribution (Unilateral vs Bilateral)	2.237	1.464-3.420	< 0.001
AFP ( ≤ 100 ng/mL vs > 100 ng/mL)	2.131	1.539-2.949	< 0.001
AFP-L3 ( ≤ 50% vs > 50%)	1.664	0.957-2.894	0.071
DCP ( ≤ 100 mAU/mL vs > 100 mAU/mL)	2.201	1.588-3.051	< 0.001
Therapeutic effect (CR + PR vs SD + PD)	3.419	2.382-4.909	< 0.001
Multivariate analysis of predictors of survival
PVTT grade (Vp0, 1, 2 vs Vp3)	2.310	1.217-4.384	0.010
AFP ( ≤ 100 ng/mL vs > 100 ng/mL)	1.856	1.265-2.724	0.002
Therapeutic effect (CR + PR vs SD + PD)	3.392	2.240-5.135	< 0.001

The JIS score is obtained by simply adding both scores for the tumor, lymph node, metastasis (TNM) stage and Child-Turcotte-Pugh stage. HCV: Hepatitis C virus; JIS: Japan integrated staging; PVTT: Portal vein tumor thrombosis; AFP: α-fetoprotein; DCP: Des-γ-carboxy prothrombin; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.